Actavis Inc., a pharmaceutical company named in a multidistrict litigation (MDL) alleging failure to warn of cardiovascular risks with testosterone replacement therapies, has reached a memorandum of understanding on a potential global settlement concerning its testosterone treatment Androderm.
Actavis is the latest testosterone manufacturer to make a move toward exiting the MDL, following similar measures by Auxilium Pharmaceuticals LLC, Eli Lilly & Co., Endo Pharmaceuticals PLC, and GlaxoSmithKline LLC.
AbbVie is the only drug company in the MDL that has yet to make an effort to resolve outstanding cases. The AndroGel manufacturer also faces the most lawsuits in the litigation.
As a result of Actavis’ announcement, Judge Matthew Kennelly ordered a stay of all filed cases involving Actavis or associated companies in order to give the parties time to work toward a global agreement. The move comes just weeks before Actavis was scheduled to face its first bellwether trial. The bellwether’s August trial date still stands.
About 6,000 cases are centralized in the Northern District of Illinois. Plaintiffs claim that the manufacturers touted the benefits of their testosterone products but failed to warn that using them could put men at an increased risk of heart attacks, strokes and blood clots, some of which could be life threatening.
Six bellwether verdicts have been reached in the MDL, to date – five naming AbbVie, and one naming Auxilium. AbbVie lost two of the trials, one resulting in a $140 million verdict. The other resulted in a $3 million verdict.